Company: CMND
Filing Date: 2025-11-26
Form Type: 424B5
Source: 0001213900-25-115106
Chunk: 21

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: 424B5
Chunk 21
---
3,942,365 Common Shares and/or pre-funded 
 warrants in the First November 2025 Offering at a public offering price of $0.20 per Common        
 Share and $0.1999 per pre-funded warrant for net proceeds of $738,000, after deducting offering    
 expenses payable by us, (iii) the issuance and sale of 5,509,768 Common Shares and/or pre-funded   
 warrants in the Second November 2025 Offering at a public offering price of $0.25 per Common       
 Share and $0.2499 per pre-funded warrant for net proceeds of approximately $1.3 million,           
 after deducting offering expenses payable by us, (iv) the issuance and sale of 10,925,000          
 Common Shares in the Third November 2025 Offering at a public offering price of $0.20 per          
 Common Share for net proceeds of approximately $2.185 million, after deducting offering expenses   
 payable by us and (v) the issuance of 2,090,987 Common Shares for aggregate gross proceeds         
 of approximately $183,000 as a result of the exercise of warrants to purchase 2,894,769 Common     
 Shares for cash and on a cashless basis issued in our financings in April 2023 and January         
 2024, as if such events had occurred on July 31, 2025 (collectively, the “Pro Forma                
 Adjustments”); and                                                                                 |

| ● | on                                                                                             
 a pro forma as adjusted basis, to give further effect to the issuance and sale of 10,810,828   
 Common Shares and/or pre-funded warrants in this offering at a public offering price of $0.12  
 per Common Share and $0.1199 per pre-funded warrant, after deducting offering expenses payable 
 by us, as if the sale had occurred on July 31, 2025.                                           |

You should read this information in conjunction with our consolidated financial statements and the related notes appearing at the end of this prospectus and the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section and other financial information contained in this prospectus.

|                          |     | As                
 of  July 31, 2025 |         |   |     |       |         |   |     |          |         |   |
|:-------------------------|:----|:------------------|--------:|:--|:----|:------|--------:|:--|:----|